Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes

Abstract

IMPORTANCE Traditionally, group medical visits (GMVs) for persons with diabetes improved glycemia by intensifying medications, which infrequently led to weight loss. Incorporating GMVs with intensive dietary change could enable weight loss and improve glycemia while decreasing medication intensity.OBJECTIVE To examine whether a program of GMVs combined with intensive weight management (WM) is noninferior to GMVs alone for change in glycated hemoglobin (HbA 1c ) level at 48 weeks (prespecified margin of 0.5%) and superior to GMVs alone for hypoglycemic events, diabetes medication intensity, and weight loss. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trial identified via the electronic medical record 2814 outpatients with type 2 diabetes, uncontrolled HbA 1c , and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 27 or higher from Veterans Affairs Medical Center clinics in Durham and Greenville, North Carolina. Between January 12, 2015, and May 30, 2017, 263 outpatients started the intervention.INTERVENTIONS Participants randomized to the GMV group (n = 136) received counseling about diabetes-related topics with medication optimization every 4 weeks for 16 weeks, then every 8 weeks (9 visits). Participants randomized to the WM/GMV group (n = 127) received low-carbohydrate diet counseling with baseline medication reduction and subsequent medication optimization every 2 weeks for 16 weeks followed by an abbreviated GMV intervention every 8 weeks (13 visits). MAIN OUTCOMES AND MEASURESOutcomes included HbA 1c level, hypoglycemic events, diabetes medication effect score, and weight at 48 weeks analyzed using hierarchical generalized mixed models to account for clustering within group sessions. RESULTS Among 263 participants (mean [SD] age, 60.7 [8.2] years; 235 [89.4%] men; 143 [54.4%] black), baseline HbA 1c level was 9.1% (1.3%) and BMI was 35.3 (5.1). At 48 weeks, HbA 1c level was improved in both study arms (8.2% in the WM/GMV arm and 8.3% in the GMV arm; mean difference, −0.1%; 95% CI, −0.5% to 0.2%; upper 95% CI, <0.5% threshold; P = .44). The WM/GMV arm had lower diabetes medication use (mean difference in medication effect score, −0.5; 95% CI, −0.6 to −0.3; P < .001) and greater weight loss (mean difference, −3.7 kg; 95% CI, −5.5 to −1.9 kg; P < .001) than did the GMV arm at 48 weeks and approximately 50% fewer hypoglycemic events (incidence rate ratio, 0.49; 95% CI, 0.27 to 0.71; P < .001) during the 48-week period. CONCLUSIONS AND RELEVANCEIn GMVs for diabetes, addition of WM using a low-carbohydrate diet was noninferior for lowering HbA 1c levels compared with conventional medication management and showed advantages in other clinically important outcomes. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01973972

Nutritional basis of type 2 diabetes remission

“…However, as metformin was continued the participants did not meet the current definition of remission (box 1). Participants in the intervention group lost 3.7 kg more than those in the comparator group and 11% (12/109) achieved HbA 1c <48 mmol/mol compared with 0/117 in the comparator group 31…”

Effectiveness of Lifestyle Intervention for Type 2 Diabetes in Primary Care: the REAL HEALTH-Diabetes Randomized Clinical Trial

“…The cost of the REAL HEALTH-Diabetes LI was approximately $1750 per person for 12 months, which is comparable with the cost of other LI programs 22,23 and very similar to a contemporaneous, less intensive, dietitian-delivered VA group medical visit nutrition counseling program (4% mean weight loss at 48 weeks; $1513 per patient per year). 24 This compares favorably to the cost of on-patent weight loss or glucose-lowering medications that are recommended to promote weight loss ($3600-$7200 or more per year for lorcaserin, SGLT2 inhibitors, or GLP-1 receptor agonists). 25 MNT intervention cost is substantially lower than either LI approach.…”

Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management

“…Similarly, a high-fat diet has been associated with increased PDAC risk [ 293 ]. In terms of intensive weight management, a recent study showed that low-carbohydrate diets had similar outcomes as with medication [ 296 ]. In terms of chemotherapy (5-FU), PDAC patients with BMI ≤ 25 were found to have a significant survival benefit (median survival increasing significantly by some 50%) which was not seen in patients with BMI > 25 [ 294 ].…”